Algenomics RZ-001 Interim Results: "No Safety Issues"

Oral Presentation at AACR 2026 on the 20th
Objective Response Rate Reaches Up to 61.5%... Complete Response Confirmed at 23%

Algenomics confirmed both efficacy and safety signals in the interim results of its hepatocellular carcinoma clinical trial.

An official from Alzinomics is presenting the clinical results of RZ-001 at the American Association for Cancer Research (AACR) 2026 held in San Diego, USA, on the 19th (local time). Alzinomics

On the 19th (local time), Algenomics announced that it had orally presented the clinical data for its RNA-based anticancer drug RZ-001 in hepatocellular carcinoma at the American Association for Cancer Research (AACR) 2026, held in San Diego, USA.

According to the company, no safety issues directly related to RZ-001 have been identified to date. Meaningful signals were observed in terms of both the depth of tumor response and response rate compared to existing immuno-oncology therapies.

In terms of safety, five Grade 3 or higher adverse events were reported. All were analyzed to be associated with the combination drugs. No serious adverse events were found to have a direct causal relationship with RZ-001.

The interim analysis showed that the objective response rate (ORR) based on RECIST criteria was 38.5% (confirmed) and 46.2% (unconfirmed). According to the modified response evaluation criteria (mRECIST), the ORR was 61.5%, and the complete response (CR) rate was 23%.

This clinical trial targeted patients with hepatocellular carcinoma who were either refractory to or unsuitable for transarterial chemoembolization and had no prior experience with systemic therapy. RZ-001 was administered in combination with atezolizumab and bevacizumab.

Sungwook Lee, CEO of Algenomics, stated, "Through this oral presentation at AACR, we were able to present the initial safety and efficacy signals and the potential of our lead pipeline, RZ-001, to the global academic community. Not only will this serve as a foundation for the individual RZ-001 pipeline, but it will also help establish the clinical utility of our RNA trans-splicing platform technology."

This content was produced with the assistance of AI translation services.